NASDAQ:REPHRecro Pharma Stock Price, Forecast & News

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, REPH shares have decreased by 52.0% and is now trading at $4.40.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Recro Pharma.

Recro Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Recro Pharma.

Recro Pharma will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Recro Pharma Inc (NASDAQ:REPH) announced its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.30. The specialty pharmaceutical company earned $21.78 million during the quarter, compared to analysts' expectations of $19.40 million. Recro Pharma had a negative net margin of 25.38% and a negative return on equity of 15.25%.
View Recro Pharma's earnings history.

Recro Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-85 million, compared to the consensus revenue estimate of $98.26 million.

2 brokers have issued 1 year price objectives for Recro Pharma's shares. Their forecasts range from $12.00 to $18.00. On average, they anticipate Recro Pharma's stock price to reach $15.00 in the next year. This suggests a possible upside of 240.9% from the stock's current price.
View analysts' price targets for Recro Pharma.

News headlines about REPH stock have trended very positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Recro Pharma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Recro Pharma.

Recro Pharma saw a drop in short interest in July. As of July 15th, there was short interest totaling 656,000 shares, a drop of 31.9% from the June 30th total of 963,000 shares. Based on an average daily volume of 563,100 shares, the short-interest ratio is currently 1.2 days. Currently, 3.3% of the shares of the company are short sold.
View Recro Pharma's Short Interest.

Some companies that are related to Recro Pharma include Kamada (KMDA), Merus (MRUS), Fulcrum Therapeutics (FULC), Atreca (BCEL), MannKind (MNKD), Ovid Therapeutics (OVID), Albireo Pharma (ALBO), BIOFRONTERA AG/ADR (BFRA), Axovant Sciences (AXON), ANI Pharmaceuticals (ANIP), Progenics Pharmaceuticals (PGNX), Calithera Biosciences (CALA), Beyondspring (BYSI), Passage Bio (IMRA) and CytomX Therapeutics (CTMX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include TherapeuticsMD (TXMD), Flexion Therapeutics (FLXN), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Novavax (NVAX).

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Recro Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.84%), GW&K Investment Management LLC (1.43%), Russell Investments Group Ltd. (0.77%), Cadence Capital Management LLC (0.71%), Strs Ohio (0.41%) and Trexquant Investment LP (0.25%). Company insiders that own Recro Pharma stock include Arnaud Ajdler and Geraldine Henwood.
View institutional ownership trends for Recro Pharma.

REPH stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., and UBS Group AG.
View insider buying and selling activity for Recro Pharma.

REPH stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Russell Investments Group Ltd., Strs Ohio, Cadence Capital Management LLC, Trexquant Investment LP, GW&K Investment Management LLC, Diversified Trust Co, and XTX Markets LLC.
View insider buying and selling activity for Recro Pharma.

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REPH stock can currently be purchased for approximately $4.40.

Recro Pharma has a market capitalization of $103.71 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Recro Pharma employs 255 workers across the globe.

The official website for Recro Pharma is www.recropharma.com.

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]